> Details

Teich, Katrin; Stadler, Michael; Gabdoulline, Razif; Kandarp, Jyoti; Wienecke, Clara; Heida, Bennet; Klement, Piroska; Büttner, Konstantin; Venturini, Letizia; Wichmann, Martin; Puppe, Wolfram; Schultze-Florey, Christian; Koenecke, Christian; Beutel, Gernot; Eder, Matthias; Ganser, Arnold; Heuser, Michael; Thol, Felicitas

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML
  • Contributor: Teich, Katrin; Stadler, Michael; Gabdoulline, Razif; Kandarp, Jyoti; Wienecke, Clara; Heida, Bennet; Klement, Piroska; Büttner, Konstantin; Venturini, Letizia; Wichmann, Martin; Puppe, Wolfram; Schultze-Florey, Christian; Koenecke, Christian; Beutel, Gernot; Eder, Matthias; Ganser, Arnold; Heuser, Michael; Thol, Felicitas
  • Published: MDPI AG, 2023
  • Published in: Cancers, 15 (2023) 15, Seite 3911
  • Language: English
  • DOI: 10.3390/cancers15153911
  • ISSN: 2072-6694
  • Origination:
  • Footnote:
  • Description: Donor lymphocyte infusions (DLIs) can directly target leukemic cells through a graft-versus-leukemia effect and play a key role in the prevention and management of relapse after allogeneic hematopoietic cell transplantation (alloHCT). Predictors of response to DLIs are not well established. We evaluated measurable residual disease (MRD) before, 30 and 90 days after DLI treatment as biomarkers of response. MRD was assessed by next-generation sequencing in 76 DLI-treated acute myeloid leukemia patients. MRD status before DLI treatment was independently prognostic for event-free survival (EFS, p < 0.001) and overall survival (OS, p < 0.001). Within 90 days of DLI treatment, 73% of MRD+ patients converted to MRD− and 32% of patients without remission achieved remission. MRD status 90 days after DLI treatment was independently prognostic for the cumulative incidence of relapse (CIR, p = 0.011) and relapse-free survival (RFS, p = 0.001), but not for OS. To evaluate the role of DLI treatment in MRD− patients, 23 MRD− patients who received DLIs were compared with a control cohort of 68 MRD− patients not receiving DLIs. RFS (p = 0.23) and OS (p = 0.48) were similar between the two cohorts. In conclusion, MRD is prognostic before (EFS, OS) and after (CIR, RFS) DLI treatment and may help in the selection of patients who benefit most from DLIs.
  • Access State: Open Access